Produção Nacional
Revisado por pares
Nanomedicine beyond tumor passive targeting: what next?
2020; Future Medicine; Volume: 15; Issue: 19 Linguagem: Inglês
10.2217/nnm-2020-0208
ISSN1748-6963
AutoresJoão Paulo Figueiró Longo, Luís Alexandre Muehlmann,
Tópico(s)Nanoparticle-Based Drug Delivery
ResumoNanomedicineVol. 15, No. 19 EditorialNanomedicine beyond tumor passive targeting: what next?João Paulo Figueiró Longo & Luís Alexandre MuehlmannJoão Paulo Figueiró Longo *Author for correspondence: Tel.: +55 61 3107 3087; Fax +55 61 9814 32755; E-mail Address: jplongo82@gmail.comhttps://orcid.org/0000-0002-5154-7263Institute of Biological Sciences, University of Brasília, Brasília – DF 70910-900, Brazil & Luís Alexandre Muehlmann https://orcid.org/0000-0003-4711-7583Faculty of Ceilândia, University of Brasília, Brasília – DF 72220-900, BrazilPublished Online:17 Jul 2020https://doi.org/10.2217/nnm-2020-0208AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: chemotherapyclinical translationclinical trialshealthcarelipid nanoparticlesliposomenanomedicineperspectivespharmacokineticspreclinical studiesReferences1. Lammers T, Ferrari M. The success of nanomedicine. Nano Today 31, 100853 (2020).Crossref, CAS, Google Scholar2. da Rocha MCO, da Silva PB, Radicchi MA et al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J. Nanobiotechnology 18(1), 1–20 (2020).Crossref, Medline, Google Scholar3. Radicchi MA, de Oliveira JV Mendes ACP et al. Lipid nanoemulsion passive tumor accumulation dependence on tumor stage and anatomical location: a new mathematical model for in vivo imaging biodistribution study. J. Mater. Chem. B 6(44), 7306–7316 (2018).Crossref, Medline, CAS, Google Scholar4. Camara ALD, Nagel G, Tschiche HR et al. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. Nanomedicine (Lond.) 12(15), 1751–1765 (2017).Link, CAS, Google Scholar5. Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv. Transl. Res. 10, 721–725 (2020).Crossref, Medline, Google Scholar6. Sindhwani S, Syed AM, Ngai J et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).Crossref, Medline, CAS, Google Scholar7. Ganassin R, Souza LRD, Py-Daniel KR et al. Decoration of a poly(methyl vinyl ether-co-maleic anhydride)-shelled selol nanocapsule with folic acid increases its activity against different cancer cell lines. J. Nanosci. Nanotechnol. 18(1), 522–528 (2018).Crossref, Medline, CAS, Google Scholar8. Wang H, Lu Z, Wang L et al. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res. 77(24), 6963–6974 (2017).Crossref, Medline, CAS, Google Scholar9. Adams D, Gonzalez-Duarte A, O'Riordan WD et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379(1), 11–21 (2018).Crossref, Medline, CAS, Google Scholar10. Kang HC, Bae YH. Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide. Biomaterials 32(21), 4914–4924 (2011).Crossref, Medline, CAS, Google Scholar11. Daeihamed M, Haeri A, Ostad SN et al. Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics. Nanomedicine (Lond.) 12(10), 1187–1202 (2017).Link, CAS, Google Scholar12. Ahmad N, Ahmad R, Alam MA, Ahmad FJ. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem. Cent. J. 12(1), 65 (2018).Crossref, Medline, CAS, Google Scholar13. Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J. Control. Rel. 141(3), 277–299 (2010).Crossref, Medline, CAS, Google Scholar14. Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. J. Pharm. Sci. 106(2), 423–445 (2017).Crossref, Medline, CAS, Google Scholar15. Coelho JM, Camargo NS, Ganassin R et al. Oily core/amphiphilic polymer shell nanocapsules change the intracellular fate of doxorubicin in breast cancer cells. J. Mater. Chem. B. 7(41), 6390–6398 (2019).Crossref, Medline, CAS, Google Scholar16. Joanitti GA, Ganassin R, Correa Rodrigues M et al. Nanostructured systems for the organelle-specific delivery of anticancer drugs. Mini Rev. Med. Chem. 17(3), 224–236 (2017).Crossref, Medline, CAS, Google Scholar17. Biswas S, Torchilin VP. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev. 66, 26–41 (2014).Crossref, Medline, CAS, Google Scholar18. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191–200 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTumor vascular heterogeneity and the impact of subtumoral nanoemulsion biodistributionJaqueline Vaz de Oliveira, Márcia Cristina Oliveira da Rocha, Ailton Antônio de Sousa-Junior, Mosar Corrêa Rodrigues, Gabriel Ribeiro Farias, Patrícia Bento da Silva, Sônia Nair Bao, Andris Figueiroa Bakuzis, Ricardo Bentes Azevedo, Paulo César Morais, Luís Alexandre Muehlmann & João Paulo Figueiró Longo28 February 2023 | Nanomedicine, Vol. 0, No. 0Recent approaches in nanocarrier‐based therapies for neglected tropical diseases25 September 2022 | WIREs Nanomedicine and NanobiotechnologyAn Overview on Immunogenic Cell Death in Cancer Biology and Therapy27 July 2022 | Pharmaceutics, Vol. 14, No. 8The Promise of Nanotechnology in Personalized Medicine22 April 2022 | Journal of Personalized Medicine, Vol. 12, No. 5Current hurdles to the translation of nanomedicines from bench to the clinic23 July 2021 | Drug Delivery and Translational Research, Vol. 12, No. 3Editorial: Nanomedicine in Cancer Targeting and Therapy25 October 2021 | Frontiers in Oncology, Vol. 11How has nanomedical innovation contributed to the COVID-19 vaccine development?João Paulo Figueiró Longo & Luis Alexandre Muehlmann11 May 2021 | Nanomedicine, Vol. 16, No. 14Issues affecting nanomedicines on the way from the bench to the market1 January 2020 | Journal of Materials Chemistry B, Vol. 8, No. 47 Vol. 15, No. 19 Follow us on social media for the latest updates Metrics Downloaded 81 times History Received 15 May 2020 Accepted 29 May 2020 Published online 17 July 2020 Published in print August 2020 Information© 2020 Future Medicine LtdKeywordschemotherapyclinical translationclinical trialshealthcarelipid nanoparticlesliposomenanomedicineperspectivespharmacokineticspreclinical studiesFinancial & competing interests disclosureThe authors are grateful for financial support from the Brazilian agencies MCTI/CNPq, FAP/DF and CAPES. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)